PRELUDE THERAPEUTICS INC (PRLD) — insider trading
Health Care · NASDAQ
PRELUDE THERAPEUTICS INC (PRLD) has 16 reported SEC Form 4 insider transactions in our data, including 6 open-market purchases among the most recent 16 (latest 2026-06-09).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-09 | FRIEDMAN PAUL A | Director | Grant / award / vesting (derivative) | 38,000 | — | $0 | Form 4 |
| 2026-06-09 | Sandor Victor | Director | Grant / award / vesting (derivative) | 38,000 | — | $0 | Form 4 |
| 2026-06-09 | Bonita David P | Director, 10% owner | Grant / award / vesting (derivative) | 38,000 | — | $0 | Form 4 |
| 2026-06-09 | Babler Martin | Director | Grant / award / vesting (derivative) | 38,000 | — | $0 | Form 4 |
| 2026-06-09 | Dorton Katina | Director | Grant / award / vesting (derivative) | 38,000 | — | $0 | Form 4 |
| 2026-06-09 | BAKER BROS. ADVISORS LP; 667, L.P.; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN | Director, 10% owner | Grant / award / vesting (derivative) | 38,000 | — | $0 | Form 4 |
| 2026-06-09 | BAKER BROS. ADVISORS LP; 667, L.P.; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN | Director, 10% owner | Grant / award / vesting (derivative) | 38,000 | — | $0 | Form 4 |
| 2026-05-01 | Morris Charles Q | Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 450,000 | $4.70 | $2.12M | Form 4 |
| 2026-04-27 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Kolchinsky Peter; Shah Rajeev M. | 10% owner | Other acquisition or disposition (derivative) | 1,407,000 | — | — | Form 4 |
| 2026-04-27 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Kolchinsky Peter; Shah Rajeev M. | 10% owner | Other acquisition or disposition | 1,407,000 | — | — | Form 4 |
| 2026-04-21 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VI LLC; ORBIMED CAPITAL LLC; OrbiMed Genesis GP LLC | Director, 10% owner | Open-market purchase | 1,126,126 | $4.44 | $5.00M | Form 4 |
| 2026-04-21 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VI LLC; ORBIMED CAPITAL LLC; OrbiMed Genesis GP LLC | Director, 10% owner | Open-market purchase | 1,689,189 | $4.44 | $7.50M | Form 4 |
| 2026-04-21 | Bonita David P | Director, 10% owner | Open-market purchase | 1,126,126 | $4.44 | $5.00M | Form 4 |
| 2026-04-21 | Bonita David P | Director, 10% owner | Open-market purchase | 1,689,189 | $4.44 | $7.50M | Form 4 |
| 2026-04-21 | BAKER BROS. ADVISORS LP; 667, L.P.; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN | Director, 10% owner | Open-market purchase (derivative) | 2,137,651 | $4.44 | $9.49M | Form 4 |
| 2026-04-21 | BAKER BROS. ADVISORS LP; 667, L.P.; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN | Director, 10% owner | Open-market purchase (derivative) | 114,601 | $4.44 | $508.8K | Form 4 |
Ask the chat about PRLD's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: PRELUDE THERAPEUTICS INC (PRLD).
Last updated 2026-06-09 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.